Presentation Summary : SGLT2 Inhibitors in Phase 3 Development Empagliflozin Canagliflozin Dapagliflozin Ipragliflozin Empagliflozin: Change in A1C Randomized, double-blind, 12 week ...
Source : http://www.nysafp.org/images/uploads/misc/1326909268_SGLT-2%20powerpoint%20AFP.ppt
Presentation Summary : Role of the Kidney in T2DM - WorldWIDE Diabetes
Source : http://www.worldwidediabetes.org/wp-content/downloads/role-of-the-kidney.ppt
Presentation Summary : * Treatment of Hypoglycemia: AACE ... glucagon secretion Slow gastric emptying Increase satiety Exenatide Byetta Exenatide XR Bydureon Liraglutide Victoza SGLT2 ...
Source : http://outpatient.aace.com/sites/all/files/T2DM_S5_Treatment_041813.ppt
Presentation Summary : Rationale for SGLT2 Inhibitors. The SGLT2 is a glucose transporter responsible for 90% of glucose reabsorption. Selective SGLT2 inhibitors could reduce blood glucose ...
Source : http://www.inosteo.org/UserFiles/File/PowerPoint/2012%20IOA%20Annual%20Convention/Saturday/Advances%20in%20Type%202%20Diabetes.Novel%20Agents%20that%20Target%20the%20Kidney.Freeman.pptx
Presentation Summary : Sodium-Glucose-Cotransporter-2 (SGLT2) Inhibitors: The Latest Class of Oral Agents. Canagliflozin and Dapagliflozin are the first FAD approved SGLT-2 In.
Source : http://adc2014.com/presentations/Osama-Hamdy/001.pptx
Presentation Summary : Model-Based Meta-Analysis of HbA1c, Weight, and FPG in Type 2 Diabetes: Focus on SGLT2 inhibitors William S. Denney and Gianluca Nucci Pfizer Global R&D, Groton/New ...
Source : http://www.go-acop.org/sites/default/files/webform/posters/Denney-SGLT-2%20Poster-ACoP%202011.ppt
Presentation Summary : The sodium-glucose cotransporter 2 (SGLT2) ... Confidence in decision making greatly enhanced by systems pharmacology resulting in clinical program acceleration
Source : http://www.go-acop.org/sites/default/files/webform/posters/Nucci-SGLT2i-Poster-ACoP-2011.ppt
Presentation Summary : Hyperglycemia in Type 2 Diabetes Sodium Glucose Cotransporters Location of Sodium Glucose Cotransporters in the Kidney SGLT2 Inhibitors Rationale for SGLT2 ...
Source : http://img.medscape.com/images/32761/779655_slides.ppt
Presentation Summary : ... Meetings Conducted in April 2009 SMQ MACE: CV-related events (serious or non-serious) based on MedDRA SMQs Custom MACE: CV-related events ...
Source : http://www.amstat.org/chapters/Northeasternillinois/pastevents/presentations/fall09_Wilson.ppt
Presentation Summary : Author: ETreventi Created Date: 08/07/2014 12:33:17 Title: The Kidney and Glucose Homeostasis: Why Target SGLT2 in Diabetes Treatment? Last modified by
Source : http://img.medscape.com/images/829/831/829831_slides.pptx
Presentation Summary : ... Dr. Howard Verrico, Sirona Biochem’s first transaction was to acquire an exclusive global license to TFChem’s SGLT2 Inhibitor ...
Source : http://www.sironabiochem.com/wp-content/uploads/2014/02/SBM-Introduction-01292014.pptx
Presentation Summary : Objectives. Pharmacists will be able to: Describe SGLT2 inhibitors. Compare available SGLT-2 inhibitors. Identifyideal candidates for SGLT2 inhibitors
Source : http://www.drsamrotation.com/uploads/1/9/8/6/19863509/jardiance_presesentation_rahul.pptx
Presentation Summary : Sodium-glucose-cotransporter-1 and -2 (SGLT1 & SGLT2) Reabsorb glucose. Renal gluconeogensis contributes 20-25% of total glucose production. Hepatic contribution.
Source : http://www.segageriatrics.com/wp/wp-content/uploads/2011/09/New-DMII-Treatments.pptx
Presentation Summary : Specific SGLT2 inhibitors are being developed as a novel means of controlling hyperglycaemia in T2DM. Contribution of Tissues to Fasting Plasma Glucose. Liver. 80%.
Source : http://familydoctornm.org/presentations/57-presentations/20140802-1030-2.pptx
Presentation Summary : Review the role of the kidney in the maintenance of normal glucose homeostasis. 6. Discuss the role of the SGLT2 inhibitors in the treatment of Type 2 DM. 7. Define ...
Source : http://www.sanap.org/Diabetes_flyer_2014_registration_form.ppt
Presentation Summary : ... Mechanism of Action Dapagliflozin (DAPA) is a selective inhibitor of the renal sodium-glucose co-transporter 2 (SGLT2) ...
Source : http://aace.newshq.businesswire.com/sites/aace.newshq.businesswire.com/files/publication/file/Shoba_Ravichandran_AACE_2011_slides.ppt
Presentation Summary : SGLT2 inhibitor. Increase urinary excretion of glucose. Canagliflozin. ... Endocr Pract. 2011;17(suppl 2):1-53. Stenlof K, et al. Diabetes Obes Metab. 2013;15:372-382.
Source : http://outpatient.aace.com/sites/all/files/T2DM-S5-Treatment-051713.pptx
Presentation Summary : SGLT2 mediates 90% of filtered glucose reabsorption in the convoluted segment of the ... Rosenstock J, HOE901/4002 Study Group. Diabetes. 2002;51(suppl 2):A113 ...
Source : http://www.acponline.org/about_acp/chapters/va/13mtg/aloi_advancementdiabetes.pptx
Presentation Summary : New SGLT2 inhibitor; new sub-class of Non-insulin Diabetes drugs. BCF Clarifications. Mesalamine delayed release (Asacol) Next Choice (emergency contraception)
Source : http://pec.ha.osd.mil/files/PECwebcast_June2013%20Final.pptx
Presentation Summary : Once daily SGLT2 inhibitor indicated as add-on therapy. Additional HgbA1c reduction -0.32% vs. -0.14% SU add-on.
Source : http://www.correctionalhealthconference.com/sites/correctionalhealthconference.com/files/Drug%20Utilization%20and%20the%20Pharmaceutical%20Pipeline_Erik%20Hamel.pptx
Presentation Summary : ... Antiplatelet therapy Annual screening of complications Diabetic education New drugs in diabetes mellitus Selective SGLT2 Inhibitors Dapagliflozin ...
Source : http://www.tlaa.org/2012/timac_rename.php?timac_pdf_id=11
Presentation Summary : ... EC & Henry RR. Nature Reviews Drug Discovery. 2010;9:551-559. Renal Glucose Transport Rationale for SGLT2 Inhibitors SGLT2 is a low-affinity, ...
Source : http://www.osteopathic.org/inside-aoa/events/omed/omed-presentations/Documents/2013%20OMED%20Presentations/cleveland-clinic-skugor-oral-antidiabetic-medications.ppt
Presentation Summary : Works as a SGLT2 inhibitor. Works at sodium-glucose cotransporter 2 in kidneys to prevent glucose being reabsorbed & thus to be lost to the urine.
Source : http://www.etsu.edu/com/cme/documents/grand_rounds/internalmedicine/Snyder.pptx
Presentation Summary : New mechanism of action - SGLT2 inhibition. Dose related A1c reductions studied as monotherapy and in combination with SFU, DPP4, TZD, Basal Insulin.
Source : http://metrohealth.net/wp-content/uploads/2012/01/Wolfe-Winter-Update-2014-DM1.pptx